Cargando…

Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia

Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd Jalil, Afdhal Afiq, Wan Muhamad Hatta, Sharifah Faradila, Mohamad, Aimi Fadilah, Abdul Rani, Mohammed Fauzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079213/
https://www.ncbi.nlm.nih.gov/pubmed/33986809
http://dx.doi.org/10.1155/2021/5544848
_version_ 1783685177652805632
author Abd Jalil, Afdhal Afiq
Wan Muhamad Hatta, Sharifah Faradila
Mohamad, Aimi Fadilah
Abdul Rani, Mohammed Fauzi
author_facet Abd Jalil, Afdhal Afiq
Wan Muhamad Hatta, Sharifah Faradila
Mohamad, Aimi Fadilah
Abdul Rani, Mohammed Fauzi
author_sort Abd Jalil, Afdhal Afiq
collection PubMed
description Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed.
format Online
Article
Text
id pubmed-8079213
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-80792132021-05-12 Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia Abd Jalil, Afdhal Afiq Wan Muhamad Hatta, Sharifah Faradila Mohamad, Aimi Fadilah Abdul Rani, Mohammed Fauzi Case Rep Med Case Report Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed. Hindawi 2021-04-19 /pmc/articles/PMC8079213/ /pubmed/33986809 http://dx.doi.org/10.1155/2021/5544848 Text en Copyright © 2021 Afdhal Afiq Abd Jalil et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Abd Jalil, Afdhal Afiq
Wan Muhamad Hatta, Sharifah Faradila
Mohamad, Aimi Fadilah
Abdul Rani, Mohammed Fauzi
Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
title Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
title_full Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
title_fullStr Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
title_full_unstemmed Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
title_short Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
title_sort denosumab as the treatment of recalcitrant tuberculous pleural effusion-associated hypercalcemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079213/
https://www.ncbi.nlm.nih.gov/pubmed/33986809
http://dx.doi.org/10.1155/2021/5544848
work_keys_str_mv AT abdjalilafdhalafiq denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia
AT wanmuhamadhattasharifahfaradila denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia
AT mohamadaimifadilah denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia
AT abdulranimohammedfauzi denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia